Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash from Operations (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Cash from Operations data on record, last reported at 13131000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 46.91% year-over-year to 13131000.0; the TTM value through Dec 2025 reached 47113000.0, down 134.68%, while the annual FY2025 figure was 47113000.0, 134.68% down from the prior year.
  • Cash from Operations reached 13131000.0 in Q4 2025 per ACRS's latest filing, down from 10932000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 22000000.0 in Q3 2024 and bottomed at 26353000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 13260700.0, with a median of 12689500.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: tumbled 214.15% in 2023, then skyrocketed 189.59% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 17075000.0 in 2021, then dropped by 11.95% to 19115000.0 in 2022, then surged by 64.63% to 6761000.0 in 2023, then plummeted by 32.2% to 8938000.0 in 2024, then crashed by 46.91% to 13131000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 13131000.0 in Q4 2025, 10932000.0 in Q3 2025, and 9993000.0 in Q2 2025.